Literature DB >> 9915282

Lessons from the Hemodialysis (HEMO) Study: an improved measure of the actual hemodialysis dose.

T Depner1, G Beck, J Daugirdas, J Kusek, G Eknoyan.   

Abstract

The Hemodialysis (HEMO) Study is a multicenter, prospective, randomized, 2 x 2 factorial clinical trial designed to evaluate the efficacy of the dose of dialysis delivered ("standard" v "high") and dialysis membrane flux ("low" v "high") in reducing the morbidity and mortality of patients. The study is nearly half complete. Although both patients and investigators are blinded to the overall findings, which will not be available for another 3 years, important data have been generated from which a more accurate expression has been derived for the dose of dialysis received by each patient in the trial. This new expression of the effectiveness of dialysis, eKt/V, is a two-pool approximation derived from the traditional single-pool Kt/V (spKt/V) and time on dialysis. The dialysis prescription for the HEMO Study subjects is individualized to achieve the target dose for each patient and is closely monitored by measuring the more accurate and validated expression of eKt/N. Comparisons of the HEMO Study dose of dialysis with other studies have been confused by this unique expression (eKt/V) of the dialysis dose and adequacy adopted for the HEMO Study. The target eKt/V dose in the "standard" arm of the Study is 1.05 and in the "high" arm is 1.45 per dialysis thrice weekly. Based on data available from 426 subjects randomized to each arm, the target of 1.05 in the "standard" dose of the HEMO Study is equivalent to an spKt/V of 1.32, and that of the "high" dose, 1.67. Thus, volunteers in the "standard" arm of the Study are receiving a tightly controlled and closely monitored dose, which is above the current national mean spKt/V, and above that of the accepted minimum standard spKt/N of 1.2. When completed, the HEMO Study will show whether there are merits of a tightly controlled hemodialysis dose that is consistently delivered over a prolonged period and whether a high dose is beneficial and safe to prescribe.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9915282     DOI: 10.1016/s0272-6386(99)70272-6

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  8 in total

1.  Aiming at averages.

Authors:  E J Will
Journal:  J R Soc Med       Date:  2001-12       Impact factor: 5.344

2.  Effects of pyrophosphate delivery in a peritoneal dialysis solution on bone tissue of apolipoprotein-E knockout mice with chronic kidney disease.

Authors:  Fellype C Barreto; Rodrigo B de Oliveira; Joyce Benchitrit; Loïc Louvet; Raja Rezg; Sabrina Poirot; Vanda Jorgetti; Tilman B Drüeke; Bruce L Riser; Ziad A Massy
Journal:  J Bone Miner Metab       Date:  2014-01-21       Impact factor: 2.626

3.  Dialysis cannot be dosed.

Authors:  Timothy W Meyer; Tammy L Sirich; Thomas H Hostetter
Journal:  Semin Dial       Date:  2011-09-19       Impact factor: 3.455

Review 4.  High-flux versus low-flux membranes for end-stage kidney disease.

Authors:  Suetonia C Palmer; Kannaiyan S Rabindranath; Jonathan C Craig; Paul J Roderick; Francesco Locatelli; Giovanni F M Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2012-09-12

Review 5.  Cellulose, modified cellulose and synthetic membranes in the haemodialysis of patients with end-stage renal disease.

Authors:  A M Macleod; M Campbell; J D Cody; C Daly; C Donaldson; A Grant; I Khan; K S Rabindranath; L Vale; S Wallace
Journal:  Cochrane Database Syst Rev       Date:  2005-07-20

6.  Reporting of "dialysis adequacy" as an outcome in randomised trials conducted in adults on haemodialysis.

Authors:  Sanne Steyaert; Els Holvoet; Evi Nagler; Simon Malfait; Wim Van Biesen
Journal:  PLoS One       Date:  2019-02-05       Impact factor: 3.240

7.  Carbamylation of serum albumin as a risk factor for mortality in patients with kidney failure.

Authors:  Anders H Berg; Christiane Drechsler; Julia Wenger; Roberto Buccafusca; Tammy Hod; Sahir Kalim; Wenda Ramma; Samir M Parikh; Hanno Steen; David J Friedman; John Danziger; Christoph Wanner; Ravi Thadhani; S Ananth Karumanchi
Journal:  Sci Transl Med       Date:  2013-03-06       Impact factor: 17.956

8.  Elevation of Interleukin-18 Correlates With Cardiovascular, Cerebrovascular, and Peripheral Vascular Events: A Cohort Study of Hemodialysis Patients.

Authors:  Chih-Hsiang Chang; Pei-Chun Fan; Chan-Yu Lin; Chia-Hung Yang; Yi-Ting Chen; Su-Wei Chang; Huang-Yu Yang; Chang-Chyi Jenq; Cheng-Chieh Hung; Chih-Wei Yang; Yung-Chang Chen
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.